Cayabyab M, Karlsson G B, Etemad-Moghadam B A, Hofmann W, Steenbeke T, Halloran M, Fanton J W, Axthelm M K, Letvin N L, Sodroski J G
Department of Cancer Immunology/AIDS, Dana-Farber Cancer Institute, Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA.
J Virol. 1999 Feb;73(2):976-84. doi: 10.1128/JVI.73.2.976-984.1999.
In vivo passage of a poorly replicating, nonpathogenic simian-human immunodeficiency virus (SHIV-HXBc2) generated an efficiently replicating virus, KU-1, that caused rapid CD4(+) T-lymphocyte depletion and AIDS-like illness in monkeys (S. V. Joag, Z. Li, L. Foresman, E. B. Stephens, L.-J. Zhao, I. Adany, D. M. Pinson, H. M. McClure, and O. Narayan, J. Virol. 70:3189-3197, 1996). The env gene of the KU-1 virus was used to create a molecularly cloned virus, SHIV-HXBc2P 3.2, that differed from a nonpathogenic SHIV-HXBc2 virus in only 12 envelope glycoprotein residues. SHIV-HXBc2P 3.2 replicated efficiently and caused rapid and persistent CD4(+) T-lymphocyte depletion in inoculated rhesus macaques. Compared with the envelope glycoproteins of the parental SHIV-HXBc2, the SHIV-HXBc2P 3.2 envelope glycoproteins supported more efficient infection of rhesus monkey peripheral blood mononuclear cells. Both the parental SHIV-HXBc2 and the pathogenic SHIV-HXBc2P 3.2 used CXCR4 but none of the other seven transmembrane segment receptors tested as a second receptor. Compared with the parental virus, viruses with the SHIV-HXBc2P 3.2 envelope glycoproteins were more resistant to neutralization by soluble CD4 and antibodies. Thus, changes in the envelope glycoproteins account for the ability of the passaged virus to deplete CD4(+) T lymphocytes rapidly and specify increased replicative capacity and resistance to neutralization.
一株复制能力差的非致病性猿猴-人类免疫缺陷病毒(SHIV-HXBc2)在体内传代后产生了一种复制高效的病毒KU-1,该病毒可导致猴子体内CD4(+) T淋巴细胞迅速耗竭并引发类似艾滋病的疾病(S. V. 乔格、Z. 李、L. 福雷斯曼、E. B. 斯蒂芬斯、L.-J. 赵、I. 阿达尼、D. M. 平森、H. M. 麦克卢尔和O. 纳拉扬,《病毒学杂志》70:3189 - 3197,1996年)。KU-1病毒的env基因被用于构建一种分子克隆病毒SHIV-HXBc2P 3.2,该病毒与非致病性SHIV-HXBc2病毒仅在12个包膜糖蛋白残基上存在差异。SHIV-HXBc2P 3.2复制高效,并在接种的恒河猴中导致CD4(+) T淋巴细胞迅速且持续的耗竭。与亲本SHIV-HXBc2的包膜糖蛋白相比,SHIV-HXBc2P 3.2的包膜糖蛋白能更有效地感染恒河猴外周血单个核细胞。亲本SHIV-HXBc2和致病性SHIV-HXBc2P 3.2均使用CXCR4作为受体,但在测试的其他7种跨膜区段受体中均未将其作为第二受体。与亲本病毒相比,具有SHIV-HXBc2P 3.2包膜糖蛋白的病毒对可溶性CD4和抗体的中和作用更具抗性。因此,包膜糖蛋白的变化解释了传代病毒迅速耗竭CD4(+) T淋巴细胞的能力,并表明其复制能力增强以及对中和作用的抗性增加。